Compare Cigna Corp (CI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Cigna Corp trades at $302.59 (market cap $80.55B), while Vertex Pharmaceuticals Incorporated trades at $477.46 (market cap $121.89B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Cigna Corp pays a 2.05% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| CI | VRTX | |
|---|---|---|
Market Cap | $80.55B | $121.89B |
Sector | Health | Health |
52-Week High | $311.00 | $529.59 |
52-Week Low | $244.41 | $366.54 |
Enterprise Value | $103.65B | $116.63B |
Dividend Yield | 2.05% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
